Credent Partners USA
At the Vanguard of Patient Recruitment Innovation

The success of clinical trials hinges on various factors, but an often overlooked one is the effectiveness of patient recruitment methods. A substantial number of clinical trials falter, not due to scientific shortcomings, but because of the inability to recruit enough patients to meet target sample sizes. This challenge is starkly illustrated by a report from Clinical Trials Arena, revealing that only 55 percent of trials achieve their enrolment goals within the designated recruitment period.

Such shortfalls lead to extended timelines, incurring substantial costs for biopharmaceutical companies— potentially amounting to $8 million in lost sales daily.

In addressing this critical issue, Credent Partners USA advocates for the strategic utilization of technology in patient recruitment. Recognizing how the digital space pays big dividends across all business sectors, the company posits that patient recruitment in clinical trials is an area ripe for digital innovation.

Central to this approach is the Medtack Patient Acceleration Platform, a brainchild of Credent Partners USA. Medtack stands out through its integration of advanced CRM and AI technologies, along with targeted social media and search engine strategies. This combination streamlines the recruitment process and enhances precision in identifying and engaging the right patient demographics.

By focusing on engagement through these digital channels, Medtack ensures a higher rate of successful patient recruitment, demonstrating the power of technology in transforming traditional approaches in clinical trials.

Co-Founder and Chief Strategy Officer Jose Puerto explains how the platform’s name, ‘Medtack,’ ingeniously encapsulates its mission and methodology. “‘MED’ highlights our focused commitment to the medical sector, while ‘TACK,’ inspired by a nautical maneuver, symbolizes the platform’s skillful navigation through the complex waters of patient recruitment. Together, it reflects our ability to deftly manage the intricate challenges of patient recruitment.”

Inside Medtack’s Integrated Recruitment Approach

Medtack represents a fusion of technological sophistication and an empathetic patient interaction process, ensuring an efficient, seamless transition from targeted advertising to nuanced prescreening.

The journey begins with strategically placed advertisements on platforms such as Facebook and Google. These ads lead to custom-designed landing pages, hosted by Medtack, where detailed trial information and engaging videos await to educate and initiate the prescreening process.

The prescreening unfolds in a tiered approach, starting with an online questionnaire that filters initial candidate suitability. Using an Institutional Review Board (IRB)- approved script, Credent Partners’ experienced team— with over 20 years of experience in medical technology marketing—delves deeper to ensure that only the most fitting participants progress to the next stage. Here, the Medtack platform’s CRM system—in adherence to HIPAA and GDPR standards—further aids in carefully managing the patient recruitment funnel.

But the innovation of Medtack truly shines in the subsequent phase, where AI comes into play. Medtack’s AI capabilities transform the arduous task of medical record review into an efficient process, distilling hundreds of pages to highlight critical inclusion criteria.

This pinpoint accuracy aids human reviewers in verifying candidate eligibility and later managing digital medical records.

This strategic data handling at their fingertips effectively dismantles the traditional bottlenecks associated with paper-based or siloed digital processes, accelerating the trial timeline.

The Medtack Edge for Startups

For startups poised to penetrate the market rapidly, Medtack emerges as an indispensable ally.

The primary challenge most startup innovators face is adhering to the stringent recruitment deadlines of phase II and III clinical trials. It’s a common scenario: they depend on clinical sites’ assurances of timely recruitment, only to encounter delays that can derail their market access plans.

Credent Partners provides a lifeline with its proprietary MEDTACK Research Portal for trial sites. This portal is not a mere conduit for candidate flow; it is carefully engineered to provide site coordinators with a stream of prescreened, consent-ready candidates. This proactive delivery system significantly curtails the typical recruitment lags. It equips each site with a secure portal that offers access to essential patient information and workflow management tools, facilitating a more efficient coordinator workflow and fostering enhanced patient communication through secure text messaging services.

The MEDTACK Sponsor Portal further empowers startups by providing a real-time view into each site’s candidate funnel. Its dashboard delivers detailed reports, allowing sponsors to make data-driven decisions swiftly. This real-time monitoring capability allows startups to strategically allocate their advertising budgets and time, focusing on high-performing sites and scaling back on those yielding lesser results. This is a critical advantage for startups where resources are precious.

Medtack stands out through its integration of advanced CRM and AI technologies, along with targeted social media and search engine strategies

Many clients attest to MEDTACK’s substantial impact, with reports of speeding up the recruitment process by up to 70 percent—a more than impressive statistics in the fast-paced startup ecosystem.

From Words to Action

The company consistently achieves transformative results in clinical trial patient recruitment, as evidenced by its successful partnership portfolio. Clients praise the platform for its intuitive design, ease of use, and tangible outcomes.

A collaboration with CVRx Inc., one of Credent Partners’ first clients, is a prime example. Faced with recruitment hurdles for its groundbreaking heart failure device trial, CVRx turned to Credent Partners. The team’s key role in the timely enrollment of the pivotal trial led to the FDA approval of CVRx’s Barostim device in 2019. In fact, CVRx’s management team was so pleased with the services that, to this day, they continue to rely on Credent Partners’ Medtack platform to design and implement their direct-to-patient commercial strategy.

Another exciting case that Credent Partners’ is currently working on involves an Israeli startup that developed a revolutionary implantable device to treat the symptoms of benign prostatic hyperplasia without sexual side effects. Despite a very rough start to their recruitment campaign, the introduction of the Medtack platform resulted in a quick turnaround. Within three months, they were able to increase the recruitment rate seven-fold, steering the trial back on track.

Not only these instances, but quantitative data from various trials using MEDTACK exhibit a pattern of increased recruitment efficiency and improvements in candidate pool quality. This data serves as tangible proof of Medtack’s impact and commitment to surmounting hurdles in the demanding clinical trial recruitment landscape.